Document is current

Any future updates will be listed below

Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): efficacy, safety and biomarker analysis of a prospective, multicentre, response-adapted study

Crossref DOI link: https://doi.org/10.1038/s41392-025-02138-6

Published Online: 2025-01-29

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark